Emiltatug ledadotin

Emiltatug ledadotin (Emi-Le; XMT-1660) is a B7-H4-targeted antibody-drug conjugate (ADC). Emiltatug ledadotin consists of a tumor-specific anti-B7-H4 monoclonal antibody Emiltatug , a linker-payload system built on the novel Dolasynthen (DS) ADC platform (HY-177541), and achieves site-specific conjugation via GlycoConnect click chemistry. Emiltatug ledadotin inhibits the growth of B7-H4-positive cancer cells. Emiltatug ledadotin can be used for the study of B7-H4-overexpressing advanced solid tumors, particularly breast, ovarian, and endometrial cancers[1].